Physician profile
David Kuppermann
NPI 1053762948
$2,808.37
in general payments reported to CMS, 2019-2025
25 companies · $362 in 2025
The $362 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $400 · 2022: $595 · 2023: $754 · 2024: $698 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,813.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $556.58 | 2022-2024 | Urolift |
| Procept Biorobotics Corporation | $408.38 | 2022-2025 | Aquabeam System, Aquabeam Robotic System |
| Argon Medical Devices, INC. | $400.00 | 2021 | |
| Edap Technomed INC | $333.33 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.26 | 2024 | Jardiance |
| Sumitomo Pharma America, INC. | $115.48 | 2023-2025 | Gemtesa |
| Accord Healthcare, INC. | $110.16 | 2023-2025 | |
| Urogen Pharma, INC. | $108.04 | 2022-2025 | Jelmyto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.28 | 2023 | Lifevest |
| Baxter Healthcare | $95.49 | 2023-2024 | Floseal, Tisseel |
| Blue Earth Diagnostics | $81.59 | 2022-2024 | |
| Glaxosmithkline, LLC. | $55.02 | 2023-2024 | Benlysta |
| Dendreon Pharmaceuticals LLC | $52.24 | 2025 | Provenge |
| Tolmar Pharmaceuticals, INC. | $37.17 | 2022 | |
| Telix Pharmaceuticals | $29.13 | 2024 | Illuccix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $27.01 | 2022 | |
| Hollister Incorporated | $25.01 | 2023 | Vapro Plus Pocket |
| Progenics Pharmaceuticals, INC. | $22.38 | 2024 | |
| Abbvie INC. | $21.44 | 2024 | |
| Olympus America INC. | $21.07 | 2022 | |
| Astellas Pharma US INC | $20.47 | 2025 | Xtandi |
| Medline Industries Lp | $20.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $18.68 | 2025 | Ultomiris |
| Endo USA, INC. | $18.53 | 2025 | Xiaflex |
| Angiodynamics, INC. | $16.63 | 2025 | Nanoknife |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kuppermann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.